Key result
Standardized measurement yields ~20-point lower post-stroke medication adherence than unstandardized estimates.
Why the study?
Reported estimates of secondary prevention medication adherence and persistence after ischemic stroke or transient ischemic attack vary considerably across studies, limiting comparison and interpretability. Inconsistencies in operational definitions and measurement approaches are likely to contribute to this variation alongside differences in patient behavior.
Does standardizing measurement specifications alter the estimated rates of adherence and persistence to secondary prevention medications in patients after ischemic stroke or transient ischemic attack?
Systematic Review (n=976,020)
Does standardizing measurement specifications alter the estimated rates of adherence and persistence to secondary prevention medications in patients after ischemic stroke or transient ischemic attack?
Standardizing measurement definitions reveals that suboptimal adherence (53.7%) and persistence (48.2%) to secondary prevention medications after ischemic stroke or TIA are much more common than conventional pooled estimates suggest.
Answers are grounded in this paper and cite their sources.
Standardized estimates indicate substantially lower real-world adherence and persistence than unstandardized pools; challenges conventional syntheses and supports standardized measurement in future studies.
OBJECTIVES: Continued use of secondary prevention medications after ischemic stroke or transient ischemic attack is an important component of long-term management. Reported estimates of adherence and persistence vary considerably across studies, limiting comparison and interpretability. Although some variation may reflect differences in patient behavior, inconsistencies in operational definitions and measurement approaches are also likely to contribute. We sought to examine sources of heterogeneity and to derive standardized estimates using a common reference measurement framework. STUDY DESIGN AND SETTING: We searched bibliographic databases, dissertations, and trial registries from inception to September 10, 2025, for routine-care studies reporting adherence or persistence to secondary prevention medications after ischemic stroke or transient ischemic attack. Cutoff-based proportions were extracted. We used 3-level hierarchical Bayesian models to characterize heterogeneity and multivariable meta-regression to evaluate associations with measurement specifications, follow-up window, medication class, region, and study-level characteristics. From the fitted model, we derived estimates standardized to a prespecified reference specification: pharmacy or administrative data, moderate definition stringency, and a 9- to 15-month follow-up window. RESULTS: The review included 141 studies; 101 (432 estimates; 976,020 participants) contributed to the quantitative synthesis. Unstandardized pooled estimates suggested that 74.1% of patients were adherent and 76.8% were persistent. Heterogeneity was substantial, with explained variation concentrated more in the measurement-related Assessment and Administration domains than in reported patient characteristics. Under the common reference specification, the model-based estimates were lower, at 53.7% for adherence and 48.2% for persistence. Standardized persistence declined from 63.3% at 1 to 4 months to 28.1% beyond 30 months. Adjusted estimates were generally lower in Asia; persistence was numerically lowest for anticoagulants, although credible intervals were wide and overlapping. CONCLUSION: A large proportion of the heterogeneity reported in medication adherence and persistence after ischemic stroke or transient ischemic attack appears to be attributable to methodological nonequivalence in how these outcomes are defined and measured. When evaluated within a standardized framework, suboptimal medication continuation appears more common than conventional pooled estimates indicate. Meaningful surveillance and benchmarking require longitudinal, standardized, and transparent measures of medication continuation rather than reliance on discharge prescribing alone. PLAIN LANGUAGE SUMMARY: After ischemic stroke or transient ischemic attack, patients are often prescribed long-term preventive medications to reduce the risk of another vascular event. These medicines are only effective if they are taken regularly and continued over time. Many studies have reported rates of medication adherence and persistence after stroke or transient ischemic attack, but the findings have varied substantially. In this study, we systematically reviewed the literature and used statistical modeling to examine why reported estimates differed across studies. We found that differences in how studies defined and measured adherence and persistence explained more variation than the patient characteristics that were reported. When estimates were recalculated under a common reference framework, the standardized values were substantially lower than conventional pooled estimates. We also found that persistence decreased markedly over time. These findings suggest that published estimates are often not directly comparable because studies use different measurement definitions and analytic approaches. Future research should improve consistency in how adherence and persistence are measured and reported. Clinicians, researchers, and policymakers should be cautious when comparing reported rates across studies or using them as benchmarks for quality of care.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) conducted a systematic review in Ischemic stroke or transient ischemic attack (n=976,020). Common reference measurement framework (pharmacy/administrative data, moderate stringency, 9-15 month follow-up) vs. Unstandardized conventional pooled estimates across heterogeneous measurement definitions was evaluated on Medication adherence and persistence to secondary prevention medications. Standardizing measurement specifications yielded lower post-stroke medication adherence and persistence than unstandardized pooled estimates.
Synapse has enriched 10 related papers. Consider them for comparative context: